Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00490620 · ClinicalTrials.gov registry record · Phase 2
Study of Combivir for Patients With Primary Biliary Cirrhosis
A Phase 2 study, sponsored by University of Alberta.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT00490620 is a Phase 2 study that has completed, run by University of Alberta. The registered enrollment target is 59 participants.
The verdict
NCT00490620, a Phase 2 study, has completed, sponsored by University of Alberta.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
This is a proof of principal study to determine whether combination anti-viral therapy with Combivir impacts on hepatic biochemistry in patients with primary biliary cirrhosis
Interventions
- DRUG Placebo
- DRUG Combination antiviral therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2004-01 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00490620
The ClinicalTrials.gov registry entry for NCT00490620 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alberta, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00490620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00490620 about?
NCT00490620 is a clinical study titled "Study of Combivir for Patients With Primary Biliary Cirrhosis". This is a proof of principal study to determine whether combination anti-viral therapy with Combivir impacts on hepatic biochemistry in patients with primary biliary cirrhosis
What is the current status of trial NCT00490620?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2004-01. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00490620?
The interventions under investigation include: Placebo (DRUG), Combination antiviral therapy (DRUG).
Who is sponsoring clinical trial NCT00490620?
This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.